AAAAAA
Results:
1-13
|
Results: 13
Authors:
Advani, R
Fisher, GA
Lum, BL
Hausdorff, J
Halsey, J
Litchman, M
Sikic, BI
Citation: R. Advani et al., A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance, CLIN CANC R, 7(5), 2001, pp. 1221-1229
Authors:
Yuen, AR
Sikic, BI
Citation: Ar. Yuen et Bi. Sikic, Clinical studies of antisense therapy in cancer, FRONT BIOSC, 5, 2000, pp. D588-D593
Authors:
Cufer, T
Pfeifer, M
Vrhovec, I
Frangez, R
Kosec, M
Mrhar, A
Grabnar, I
Golouh, R
Vogric, S
Sikic, BI
Citation: T. Cufer et al., Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin, ANTI-CANC D, 11(4), 2000, pp. 303-309
Authors:
Dahl, GV
Lacayo, NJ
Brophy, N
Dunussi-Joannopoulos, K
Weinstein, HJ
Chang, MR
Sikic, BI
Arceci, RJ
Citation: Gv. Dahl et al., Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia, J CL ONCOL, 18(9), 2000, pp. 1867-1875
Authors:
Lum, BL
Kaubisch, S
Fisher, GA
Brown, BW
Sikic, BI
Citation: Bl. Lum et al., Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance, CANC CHEMOT, 45(4), 2000, pp. 305-311
Authors:
Chen, GK
Lacayo, NJ
Duran, GE
Cohen, D
Sikic, BI
Citation: Gk. Chen et al., Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant p-glycoprotein with deleted Phe(335), MOLEC PHARM, 57(4), 2000, pp. 769-777
Authors:
Yuen, AR
Halsey, J
Fisher, GA
Holmlund, JT
Geary, RS
Kwoh, TJ
Dorr, A
Sikic, BI
Citation: Ar. Yuen et al., Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer, CLIN CANC R, 5(11), 1999, pp. 3357-3363
Authors:
Sikic, BI
Citation: Bi. Sikic, The First Central European Oncology Congress, Opatija, Croatia, 1998, ANN ONCOL, 10, 1999, pp. 1-1
Authors:
Sikic, BI
Citation: Bi. Sikic, New approaches in cancer treatment, ANN ONCOL, 10, 1999, pp. 149-153
Authors:
Sikic, BI
Citation: Bi. Sikic, Modulation of multidrug resistance: A paradigm for translational clinical research, ONCOLOGY-NY, 13(5A), 1999, pp. 183-187
Authors:
Dumontet, C
Sikic, BI
Citation: C. Dumontet et Bi. Sikic, Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death, J CL ONCOL, 17(3), 1999, pp. 1061-1070
Authors:
Tallman, MS
Lee, S
Sikic, BI
Paietta, E
Wiernik, PH
Bennett, JM
Rowe, JM
Citation: Ms. Tallman et al., Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia - An Eastern Cooperative Oncology Group Pilot Study, CANCER, 85(2), 1999, pp. 358-367
Authors:
Advani, R
Saba, HI
Tallman, MS
Rowe, JM
Wiernik, PH
Ramek, J
Dugan, K
Lum, B
Villena, J
Davis, E
Paietta, E
Litchman, M
Sikic, BI
Greenberg, PL
Citation: R. Advani et al., Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar), BLOOD, 93(3), 1999, pp. 787-795
Risultati:
1-13
|